Oramed Pharmaceuticals has completed a strategic $36.9 million investment in Alpha Tau Medical, acquiring approximately 14.1 million ordinary shares at $2.612 per share. The investment establishes a comprehensive partnership between two companies pioneering innovative therapeutic delivery technologies.
The collaboration, announced on April 28, 2025, centers on accelerating the development and commercialization of Alpha Tau's Alpha DaRT® technology, an alpha-radiation cancer therapy designed for the treatment of solid tumors. Under the three-year service agreement, Oramed will provide Alpha Tau with investor outreach, strategic business guidance, and capital markets expertise.
"This strategic alliance with Alpha Tau represents an exceptional opportunity for Oramed to apply our capital markets and business development expertise in supporting what we believe is a truly groundbreaking medical technology," said Nadav Kidron, CEO of Oramed Pharmaceuticals. "Both companies share a fundamental vision of revolutionizing therapeutic delivery – Oramed through oral administration of injectable drugs and Alpha Tau through precise delivery of radiation therapy to tumor sites."
Strategic Alignment in Therapeutic Delivery Innovation
The partnership brings together two companies with complementary approaches to therapeutic delivery challenges. Oramed has developed its Protein Oral Delivery (POD™) technology platform to enable oral administration of drugs traditionally delivered by injection. Alpha Tau's Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) technology provides targeted alpha radiation directly to tumor sites.
As part of the agreement, Oramed will take an active governance role with the appointment of two directors to Alpha Tau's Board of Directors, signaling a deep commitment to the partnership beyond financial investment.
Uzi Sofer, CEO of Alpha Tau, emphasized the timing of the collaboration: "This investment comes at the perfect time for Alpha Tau given the rapid expansion of our business activities, including four parallel trial approvals in the U.S., expansion into trials in multiple internal organs, and continued expansion of our manufacturing capacity and pre-commercial preparations."
Alpha DaRT Technology and Clinical Progress
Alpha Tau's Alpha DaRT technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University. Founded in 2016, the Israeli oncology therapeutics company has been advancing the technology through clinical development for treating solid tumors.
The technology delivers high-energy alpha particles with precision to tumor sites while minimizing damage to surrounding healthy tissue. This approach offers potential advantages over conventional radiation therapies, particularly for tumors in sensitive locations or those resistant to standard treatments.
The company is currently conducting clinical trials across four indications in the United States and expanding trials to address tumors in multiple internal organs. These developments, coupled with manufacturing scale-up and pre-commercialization efforts, position Alpha Tau at a critical growth stage that will benefit from Oramed's strategic support.
Market and Financial Implications
For Oramed, the investment aligns with its growth strategy to expand its footprint in innovative therapeutic delivery technologies. The company, which trades on both Nasdaq (ORMP) and the Tel Aviv Stock Exchange (ORMP), brings significant capital markets expertise to the partnership.
Alpha Tau Medical, trading on Nasdaq under the symbol DRTS, gains not only financial resources but also strategic guidance to navigate the complex path toward commercialization of its novel cancer therapy platform.
The $36.9 million investment was executed through a registered direct offering, with an Oramed affiliate purchasing the shares. This structure provides Alpha Tau with immediate capital while establishing a framework for ongoing collaboration.
Future Outlook
Both companies expressed optimism about the long-term potential of the partnership. Kidron noted, "We hold unwavering confidence in the exceptional potential of the Alpha DaRT technology platform and the strategic vision of Alpha Tau's leadership team. We anticipate significant advancements and milestone achievements as they execute their clinical and commercial roadmap."
The collaboration comes at a time when innovative approaches to cancer treatment are increasingly valuable in addressing unmet medical needs. Alpha Tau's focus on solid tumors addresses a significant area of oncology where new therapeutic options are needed.
As Alpha Tau advances its clinical programs and manufacturing capabilities, Oramed's strategic guidance and capital markets expertise may prove instrumental in navigating regulatory pathways and preparing for potential commercial launch of the Alpha DaRT technology.
